Loratadine versus levocetirizine in chronic idiopathic urticaria: A comparative study of efficacy and safety

Anuradha, P; Maiti, Rituparna; Jaida, Jyothirmai; Mujeebuddin, Omer; Anuradha, M

doi:10.4103/0253-7613.62399

Cited by 19 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean total symptom score is a widely accepted and reliable tool to assess the efficacy of a drug in the treatment of urticaria and a decrease in the scoring suggests that there is an overall clinical improvement in the condition. [ 19 ] We observed significant difference in parameters such as MNW, MPS and MTSS after completion of the treatment in rupatadine as well as olopatadine group. No rescue medication was needed in any of the patient.…”

Section: Discussionmentioning

confidence: 86%

Comparison of efficacy, safety and cost-effectiveness of rupatadine and olopatadine in patients of chronic spontaneous urticaria: A randomized, double-blind, comparative, parallel group trial

et al. 2016

View full text Add to dashboard Cite

Objective:To compare efficacy, safety and cost-effectiveness of rupatadine and olopatadine in patients of chronic spontaneous urticaria.Materials and Methods:A 6-week, single-centered, randomized, double blind, parallel group comparative clinical study was conducted on patients with chronic spontaneous urticaria. Following inclusion and exclusion criteria, 60 patients were recruited and were randomized to two treatment groups and received the respective drugs for 6 weeks. At follow-up, parameters assessed were mean total symptom score (MTSS) calculated by adding the mean number of wheals (MNW) and the mean pruritus score (MPS), number of wheals, size of wheal, scale for interference of wheals with sleep (SIWS).Results:Both the drugs significantly reduced the MTSS, number of wheals, size of wheal, scale for interference of wheals with sleep, but olopatadine was found to be superior. In olopatadine group, there was significantly higher reduction in MTSS (p = 0.01), Number of wheals (P < 0.05), Size of wheals (p < 0.05), Scale for intensity of erythema (p < 0.05) and change in eosinopils count (p = 0.015) than that of rupatadine. Incidence of adverse effects was found to be less in olopatadine group when compared with rupatadine group. Cost effectiveness ratio was less in olopatadine group as compared to rupatadine group throughout the treatment.Conclusions:Olopatadine is a better choice in chronic spontaneous urticaria in comparison to rupatadine due to its better efficacy, safety and cost effectiveness profile.

show abstract

Section: Discussionmentioning

confidence: 86%

Comparison of efficacy, safety and cost-effectiveness of rupatadine and olopatadine in patients of chronic spontaneous urticaria: A randomized, double-blind, comparative, parallel group trial

et al. 2016

View full text Add to dashboard Cite

show abstract

“…15 studies included information regarding the discontinuation of systemic corticosteroids prior to the commencement of the trial. One study, Anuradha et al stopped systemic corticosteroids for 4 weeks and the mean eosinophil % was 4.2% (n = 60), while the median was 364 10 6 /L [ 23 ]. Another study, Dakhale et al, stopped systemic corticosteroids for 8 weeks and the mean eosinophil % was 6.8% (n = 64) [ 24 ].…”

Section: Resultsmentioning

confidence: 99%

“…Where corticosteroids weren’t held, the mean eosinophil percentage, mean absolute eosinophil count and median absolute eosinophil count were not elevated. Studies did find that antihistamines reduced peripheral blood eosinophil counts in CSU subjects which may help explain these findings [ 23 , 24 , 50 ].…”

Section: Discussionmentioning

confidence: 99%

Presence of positive skin prick tests to inhalant allergens and markers of T2 inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review

Wong

Keith

2020

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

Background: Current guidelines do not recommend performing aeroallergen skin prick testing (SPT) in chronic spontaneous urticaria (CSU). Objective: The objective of this review was to investigate the presence of aeroallergen sensitization and markers of T2 inflammation in subjects with CSU. Methods: Systematic literature reviews to identify all studies that evaluated the presence of T2 markers of allergic inflammation in CSU subjects were performed. Results: In 16 studies that assessed the prevalence of positive SPT to multiple aeroallergens in CSU, 38.5% of CSU subjects had positive SPT. In three controlled studies, 34.2% of CSU subjects had positive SPT to multiple aeroallergens, compared to 13.6% of controls (p = 0.047). In 18 studies that assessed the prevalence of house dust mite (HDM) positive SPT in CSU, 27.5% of CSU subjects had positive SPT. In three controlled studies, 27.5% of CSU subjects had positive SPT to HDM, compared to 2.1% of controls (p = 0.047). Overall, CSU subjects were 3.1 times more likely to be aeroallergen-sensitized (95% CI 1.7-5.8, p = 0.0002) and 6.1 times more likely to be HDM-sensitized (95% CI 3.7-9.9, p < 0.00001) than controls. Mean total serum IgE (tIgE) levels were 238 kU/L and median tIgE levels were 164 kU/L, which was greater than the upper 90 th percentile of normal (< 137 kU/L). Compared to healthy controls, CSU subjects were 6.5 times more likely to have IgG autoantibody against FcεR1α (p = 0.001), 2.4 times more likely to have IgG anti-IgE antibody (p = 0.03) and 5 times more likely to have anti-thyroid peroxidase (anti-TPO) antibody (p = 0.02). When corticosteroids were withheld for ≥ 28 days, mean blood eosinophil percentage was elevated at 5.9% (normal < 4%), but other studies reporting absolute count found the mean was in the normal range, 239 ×10 6 / L (normal < 400 ×10 6 /L). Conclusion: Increased aeroallergen sensitization, tIgE, autoantibodies and blood eosinophil percentage in the CSU subjects indicates the possible importance of T2 inflammation in the pathogenesis of CSU. Further studies may

show abstract

“…The patients are at constant apprehension of this temperamental disease which at times waxes and wanes. There have been many studies which compare the efficacy of various second generation antihistamines,[ 1 2 3 ] the first line treatment for chronic urticaria. [ 4 ] However, the effectiveness of antihistamines is limited during the period of its use; so search for a therapeutic modality that can provide extended relief and reduce pill burden is the need of the hour.…”

Section: Introductionmentioning

confidence: 99%

Autologous serum therapy in chronic urticaria: A promising complement to antihistamines

et al. 2014

View full text Add to dashboard Cite

Background:Chronic urticaria (CU) is a vexing problem and patients of CU suffer from the morbidity that arise from irritable itch and weals and are also subjected to a huge antihistamine pill burden. The symptoms are more in autoreactive urticaria (AU) where auto-antibodies in blood flares-up the condition. Search for newer effective modalities which can reduce pill burden is a felt need.Aims:This study evaluates the effectiveness of autologous serum therapy (AST) in CU and also determines its usefulness in AU.Materials and Methods:Double blind, parallel group, randomized, controlled study. Fifty four patients were given AST and 57 patients were given injection normal saline (placebo), along with cetirizine in an on-demand basis in both groups. AST/Placebo was given weekly for nine weeks and followed-up for a total period of 24 weeks. AU was diagnosed by autologous serum skin test. Urticaria total severity score (TSS), Urticaria activity score (UAS), Dermatologic life quality index (DLQI) was used as primary effectiveness variables. Safety parameters assessed were the spontaneously reported adverse events and laboratory parameters.Results:TSS showed significant improvement from baseline, 7th week and 8th week onwards in AST group and placebo group respectively. Group comparison showed significant improvement 4th week onwards. UAS showed similar results. DLQI showed significant improvement in AST group compared to placebo at the end of study. Both AU and non-AU patients showed comparable improvement of TSS.Conclusion:AST shows promise in treatment of urticaria regardless of the autoreactive nature.

show abstract

Loratadine versus levocetirizine in chronic idiopathic urticaria: A comparative study of efficacy and safety

Cited by 19 publications

References 15 publications

Comparison of efficacy, safety and cost-effectiveness of rupatadine and olopatadine in patients of chronic spontaneous urticaria: A randomized, double-blind, comparative, parallel group trial

Comparison of efficacy, safety and cost-effectiveness of rupatadine and olopatadine in patients of chronic spontaneous urticaria: A randomized, double-blind, comparative, parallel group trial

Presence of positive skin prick tests to inhalant allergens and markers of T2 inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review

Autologous serum therapy in chronic urticaria: A promising complement to antihistamines

Contact Info

Product

Resources

About